FAG
EDIT icon

Fortitude Advisory Group’s Editas Medicine EDIT Stock Holding History

Fortitude Advisory Group’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-721
Closed -$14K – 499
2022
Q1 		$14K Hold
721
– – 0.01% 933
2021
Q4 		$19K Buy
+721
New +$24.8K 0.01% 853

Other funds holding EDIT

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Fortitude Advisory Group's EDIT Position: Q2 2022 in Review

Fortitude Advisory Group sold out of Editas Medicine (EDIT) in Q2 2022, closing a stake of 721 shares — an estimated $14K sold.

Fortitude Advisory Group first reported a position in EDIT in Q4 2021 and held it in 2 quarters. The position peaked at $19K in Q4 2021. 256 funds tracked by Wall St. Rank hold EDIT as of Q2 2022.

  • Fortitude Advisory Group reported no remaining Editas Medicine position as of Q2 2022 after selling out during the quarter.
  • Fortitude Advisory Group sold 721 Editas Medicine shares in Q2 2022, an estimated $14K.
  • Fortitude Advisory Group first reported a position in Editas Medicine in Q4 2021 and held it in 2 quarters.
  • Fortitude Advisory Group's Editas Medicine position peaked at $19K in Q4 2021.
  • 256 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2022.

Based on Fortitude Advisory Group's 13F filing for Q2 2022, filed 16 Aug 2022.